Literature DB >> 9219701

Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism.

J H Rand1, X X Wu, H A Andree, C J Lockwood, S Guller, J Scher, P C Harpel.   

Abstract

BACKGROUND: The mechanisms of vascular thrombosis and pregnancy loss in the antiphospholipid-antibody syndrome are unknown. Levels of annexin V, a phospholipid-binding protein with potent anticoagulant activity, are markedly reduced on placental villi from women with this syndrome. Hypercoagulability in such women may therefore be due to the reduction of surface-bound annexin V by antiphospholipid antibodies. To test this idea, we studied how antiphospholipid antibodies affect levels of annexin V on cultured trophoblasts and human umbilical-vein endothelial cells and how they affect the procoagulant activity of these cells.
METHODS: We isolated IgG fractions from three patients with the antiphospholipid-antibody syndrome and from normal controls. These antibodies were incubated with cultured BeWo cells (a placental-trophoblast cell line), primary cultured trophoblasts, and human umbilical-vein endothelial cells. Annexin V on the cell surfaces was measured by an enzyme-linked immunosorbent assay. The coagulation times of plasma overlaid on the cells were also determined.
RESULTS: Trophoblasts and endothelial cells exposed to antiphospholipid-antibody IgG as compared with control IgG had reduced levels of annexin V (trophoblasts, 0.37 +/- 0.02 vs. 0.85 +/- 0.12 ng per well, P=0.02; endothelial cells, 1.6 +/- 0.04 vs. 2.1 +/- 0.05 ng per well, P=0.001). Also, trophoblasts and endothelial cells exposed to antiphospholipid-antibody IgG had faster mean (+/- SE) plasma coagulation times than cells exposed to control IgG (trophoblasts, 8.7 +/- 2.0 vs. 21.3 +/- 2.9 minutes, P=0.02; endothelial cells, 9.8 +/- 0.8 vs. 14.2 +/- 1.2 minutes, P=0.04).
CONCLUSIONS: Antiphospholipid antibodies reduce the levels of annexin V and accelerate the coagulation of plasma on cultured trophoblasts and endothelial cells. The reduction of annexin V levels on vascular cells may be an important mechanism of thrombosis and pregnancy loss in the antiphospholipid-antibody syndrome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9219701     DOI: 10.1056/NEJM199707173370303

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  59 in total

1.  How to treat women with antiphospholipid antibodies in pregnancy?

Authors:  R H Derksen; P G De Groot; H K Nieuwenhuis; G C Christiaens
Journal:  Ann Rheum Dis       Date:  2001-01       Impact factor: 19.103

Review 2.  Update on the management of the pregnant patient with antiphospholipid antibody.

Authors:  L R Sammaritano
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

3.  Complement system on the attack in autoimmunity.

Authors:  John P Atkinson
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

4.  Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin.

Authors:  Yao-Hsu Yang; Kwan-Ki Hwang; John FitzGerald; Jennifer M Grossman; Mihaela Taylor; Bevra H Hahn; Pojen P Chen
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

Review 5.  Intravenous immunoglobulin therapy in antiphospholipid syndrome.

Authors:  Emiliana Konova
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

6.  Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome.

Authors:  Cai-Sheng Lu; Arash A Horizon; Kwan-Ki Hwang; John FitzGerald; Wei-Shiang Lin; Bevra H Hahn; Daniel J Wallace; Allan L Metzger; Michael H Weisman; Pojen P Chen
Journal:  Arthritis Rheum       Date:  2005-12

7.  Antiphospholipid antibodies, brain infarcts, and cognitive and motor decline in aging (ABICMA): design of a community-based, longitudinal, clinical-pathological study.

Authors:  Zoe Arvanitakis; Robin L Brey; Jacob H Rand; Julie A Schneider; Sue E Leurgans; Lei Yu; Aron S Buchman; Konstantinos Arfanakis; Debra A Fleischman; Patricia A Boyle; David A Bennett; Steven R Levine
Journal:  Neuroepidemiology       Date:  2012-10-24       Impact factor: 3.282

Review 8.  The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome.

Authors:  Rohan Willis; E B Gonzalez; A R Brasier
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

9.  Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; E Anagnostopoulou; H Kritikos; I A Mouzas; E A Kouroumalis; O N Manousos
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

10.  Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.

Authors:  Jacob H Rand; Xiao-Xuan Wu; Anthony S Quinn; Anthony W Ashton; Pojen P Chen; James J Hathcock; Harry A M Andree; Douglas J Taatjes
Journal:  Blood       Date:  2009-11-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.